Novartis applauds declaration of CML Awareness Day in Canada

Today is a meaningful milestone for chronic myelogenous leukemia (CML) patients and their families.

Thanks to the CML Society of Canada, a not-for-profit patient education and support organization, September 22^nd has been declared CML Awareness Day in Canada. Joy Smith, Member of Parliament and Chair of the House of Commons Standing Committee on Health, has recognized this day in the House of Commons and supports the efforts of the CML Society of Canada. Novartis congratulates the CML Society for their creation and recognition of this important day.

CML is one of four types of leukemia.  It is the first cancer for which scientists were able to identify the genetic anomaly involved - the Philadelphia chromosome - a discovery that led to the development of the first targeted cancer therapy. The date of September 22^nd (09/22) was chosen for CML Awareness Day because the Philadelphia chromosome is formed when chromosomes 9 and 22 exchange some of their genetic material.

"We are proud to support CML Awareness Day to promote leukemia awareness and education," says Alain Dostie, General Manager of Oncology at Novartis Pharmaceuticals Canada Inc. "Novartis will continue its development of innovative treatment options that allow patients to effectively manage their cancer and is committed to pursuing its important research into finding a cure for CML."

Source: NOVARTIS PHARMACEUTICALS CANADA INC.